LCM
DOVA

Laurion Capital Management’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Laurion Capital Management’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10,000
Closed -$243K – 1994
2017
Q3 		$243K Hold
10,000
– – ﹤0.01% 1388
2017
Q2 		$223K Buy
+10,000
New +$211K ﹤0.01% 1520

Other funds holding DOVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return

Laurion Capital Management's DOVA Position: Q4 2017 in Review

Laurion Capital Management sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2017, closing a stake of 10,000 shares — an estimated $243K sold.

Laurion Capital Management first reported a position in DOVA in Q2 2017 and held it in 2 quarters. The position peaked at $243K in Q3 2017. 48 funds tracked by Wall St. Rank hold DOVA as of Q4 2017.

  • Laurion Capital Management reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Laurion Capital Management sold 10,000 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2017, an estimated $243K.
  • Laurion Capital Management first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 2 quarters.
  • Laurion Capital Management's Dova Pharmaceuticals, Inc. Common Stock position peaked at $243K in Q3 2017.
  • 48 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2017.

Based on Laurion Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.